Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older

Healthy, varicella-zoster virus (VZV)-seropositive subjects, aged 55–89 years (mean age 66 years), received either 4000 PFU of live, attenuated VZV vaccine ( n=85) or an equal volume of this vaccine that was heat-inactivated ( n=82). Both vaccines significantly boosted VZV antibody (enzyme immunoass...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2000-06, Vol.18 (25), p.2915-2920
Main Authors: Levine, Myron J, Ellison, Misoo C, Zerbe, Gary O, Barber, Deb, Chan, Christina, Stinson, Diane, Jones, Michelle, Hayward, Anthony R
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Antibodies, Viral - biosynthesis
Biological and medical sciences
Cell-mediated immune response
Chickenpox Vaccine - administration & dosage
Chickenpox Vaccine - immunology
Epidemiology. Vaccinations
Follow-Up Studies
Fundamental and applied biological sciences. Psychology
g-Interferon
General aspects
Herpes Zoster - immunology
Herpes Zoster - prevention & control
Herpes zoster prevention
Herpesvirus 3, Human - immunology
Humans
Immunization, Secondary - methods
Infectious diseases
Medical sciences
Microbiology
Middle Aged
Random Allocation
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
Vaccines, Attenuated - administration & dosage
Vaccines, Attenuated - immunology
Vaccines, Inactivated - administration & dosage
Vaccines, Inactivated - immunology
Varicella vaccine
varicella-zoster virus 1
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Healthy, varicella-zoster virus (VZV)-seropositive subjects, aged 55–89 years (mean age 66 years), received either 4000 PFU of live, attenuated VZV vaccine ( n=85) or an equal volume of this vaccine that was heat-inactivated ( n=82). Both vaccines significantly boosted VZV antibody (enzyme immunoassay) and γ-interferon production by peripheral blood mononuclear cells stimulated by VZV antigen. These responses returned to baseline by 12 months. Circulating mononuclear cells that proliferated in response to VZV antigen were significantly more numerous (responder cell frequency assay) after either vaccine, and persisted with a half-life of 17.5–21.3 months. There were no differences in immune response to either vaccine in this older age cohort.
ISSN:0264-410X
1873-2518
DOI:10.1016/S0264-410X(99)00552-6